The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 75, Issue 6, 2016, Pages 1003-1008

  Hazlewood, Glen S ^a,b,c   Thorne, J Carter ^d   Pope, Janet E ^e   Lin, Daming ^f   Tin, Diane ^d   Boire, Gilles ^g   Haraoui, Boulos ^h   Hitchon, Carol A ⁱ   Keystone, Edward C ^f   Jamal, Shahin ^j   Bykerk, Vivian P ^f,k  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d SOUTHLAKE REGIONAL HEALTH CENTRE   (Canada)

^e WESTERN UNIVERSITY   (Canada)

^f MOUNT SINAI HOSPITAL   (Canada)

^g CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^h CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

ⁱ UNIVERSITY OF MANITOBA   (Canada)

^j UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^k HOSPITAL FOR SPECIAL SURGERY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; ANTIRHEUMATIC AGENT;

ADULT; ARTICLE; COMPARATIVE STUDY; DAS28; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; EARLY RHEUMATOID ARTHRITIS; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; COMPARATIVE EFFECTIVENESS; CUTANEOUS DRUG ADMINISTRATION; LONGITUDINAL STUDY; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT FAILURE;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COMPARATIVE EFFECTIVENESS RESEARCH; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; METHOTREXATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT FAILURE;

EID: 84969964172     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-206504     Document Type: Article

References (27)

1. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
2. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625-39.
3. Bykerk VP, Akhavan P, Hazlewood GS, et al. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol 2012;39:1559-82.
4. Pincus T, Yazici Y, Sokka T, et al. Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 2003;21(5 Supplement 31):S179-85.
5. Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312:818-22.
6. De Jong PH, Hazes JM, Barendregt PJ, et al. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Ann Rheum Dis 2013;72:72-8.
7. Wevers-De Boer K, Visser K, Heimans L, et al. Remission induction therapy with methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis (the IMPROVED study). Ann Rheum Dis 2012;71:1472-7.
8. Visser K, Katchamart W, Loza E, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009;68:1086-93.
9. Schiff MH, Jaffe JS, Freundlich B. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses >/=15 mg may be overcome with subcutaneous administration. Ann Rheum Dis 2014;73:1549-51.
10. Pichlmeier U, Heuer KU. Subcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexate. Clin Exp Rheumatol 2014;32:563-71.
11. Braun J, Kastner P, Flaxenberg P, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008;58:73-81.
12. Wegrzyn J, Adeleine P, Miossec P. Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis. Ann Rheum Dis 2004;63:1232-4.
13. Rozin A, Schapira D, Balbir-Gurman A, et al. Relapse of rheumatoid arthritis after substitution of oral for parenteral administration of methotrexate. Ann Rheum Dis 2002;61:756-7.
14. Scott D, Claydon P, Ellis C. Retrospective evaluation of continuation rates following a switch to subcutaneous methotrexate in rheumatoid arthritis patients failing to respond to or tolerate oral methotrexate: the MENTOR study. Scand J Rheumatol 2014;43:470-6.
15. Sox HC, Helfand M, Grimshaw J, et al. Comparative effectiveness research: challenges for medical journals. PLoS Med 2010;7:e1000269.
16. Von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370:1453-7.
17. Bykerk VP, Jamal S, Boire G, et al. The Canadian Early Arthritis Cohort (CATCH): patients with new-onset synovitis meeting the 2010 ACR/EULAR classification criteria but not the 1987 ACR classification criteria present with less severe disease activity. J Rheumatol 2012;39:2071-80.
18. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8.
19. Prevoo ML, Van 't Hof MA, Kuper HH, et al.Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
20. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982;9:789-93.
21. Barra L, Pope J, Bessette L, et al. Lack of seroconversion of rheumatoid factor and anti-cyclic citrullinated peptide in patients with early inflammatory arthritis: a systematic literature review. Rheumatology (Oxford) 2011;50:311-16.
22. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963-74.
23. Littell RC, Pendergast J, Natarajan R. Modelling covariance structure in the analysis of repeated measures data. Stat Med 2000;19:1793-819.
24. Harris JA, Bykerk VP, Hitchon CA, et al. Determining best practices in early rheumatoid arthritis by comparing differences in treatment at sites in the Canadian Early Arthritis Cohort. J Rheumatol 2013;40:1823-30.
25. Guyatt GH, Oxman AD, Sultan S, et al. GRADE guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol 2011;64:1311-16.
26. Striesow F, Brandt A. Preference, satisfaction and usability of subcutaneously administered methotrexate for rheumatoid arthritis or psoriatic arthritis: results of a postmarketing surveillance study with a high-concentration formulation. Ther Adv Musculoskelet Dis 2012;4:3-9.
27. Hassanzadeh R, Mangan C, France J, et al. Subcutaneous methotrexate to cut costs? J Rheumatol 2012;39:1764-5.